医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Toyoda Gosei Develops Deep UV LED Light Module for Sterilization

2020年07月22日 PM01:00
このエントリーをはてなブックマークに追加


 

KIYOSU, Japan

Toyoda Gosei Co., Ltd. (TOKYO: 7282) has developed a deep UV LED light module for use in the sterilization of water, air, and surfaces. These new modules take advantage of the technology that the company has accumulated over 30 years in the development and production of blue LEDs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200721005973/en/

Deep UV LED light modules (Photo: Business Wire)

Deep UV LED light modules (Photo: Business Wire)

Deep UV LEDs emit short wavelength ultraviolet light that can destroy the genetic materials of viruses and bacteria. They are promising as a new sterilizing light source that can be used in place of mercury lamps, for which there is environmental concern.

With the aim of spreading applications of this technology, Toyoda Gosei has been developing products in modules or units with waterproof or heat dissipation features. In a joint experiment conducted with the Biomedical Science Association* using human coronavirus 229E (HCoV-229E), which has genetic materials similar to those of the virus that causes Covid-19 (SARS-CoV2), these modules were demonstrated to be highly effective in sterilization.

Toyoda Gosei is cooperating with the Toyota Group and other companies to develop applications for water, air and surface sterilization that contribute to safer and healthier living. The company will continue to contribute to the creation of a sustainable society through the core technologies it has cultivated.

*Certified NPO in Japan made up of specialists from national research institutes and universities in the fields of medicine, pharmaceutics, veterinary medicine, agriculture and more

View source version on businesswire.com: https://www.businesswire.com/news/home/20200721005973/en/

CONTACT

Toyoda Gosei Co., Ltd.

Chihiro Suzuki

inquiry@mail.toyoda-gosei.co.jp

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表